What Vilon Is
Vilon is a synthetic dipeptide, Lys-Glu, and one of the shortest members of the peptide bioregulator family. At two residues it sits at the extreme short end even within a family defined by brevity, and it is associated in the published literature with thymic and immune tissue.
It also has something most compounds in this family lack: a body of published animal work that names it directly, including long-term carcinogenesis studies. That makes it one of the few bioregulators where specific claims can be traced to specific experiments.
Research use only. Vilon is supplied for laboratory research. It is not for human or veterinary use, holds no marketing authorisation in any jurisdiction, and nothing below is guidance for administration.
What the Published Studies Report
Spontaneous tumour development and lifespan in mice
The most cited work reports that the synthetic dipeptide inhibited growth of spontaneous tumours and increased lifespan in mice (Khavinson et al., Dokl Biol Sci 2000, PMID 10944717). This is a whole-animal, long-duration design rather than a cell-culture endpoint, which is why it anchors most later discussion of the compound.
Induced carcinogenesis models
Two independent reports from the same group extend the observation to chemically induced models: an inhibitory effect on development of induced urinary bladder tumours in rats (Pliss et al., Bull Exp Biol Med 2001, PMID 11586406) and an effect on 1,2-dimethylhydrazine-induced neoplasia (Pliss et al., Vopr Onkol 2005, PMID 16308980).
Read these as what they are: rodent chemoprevention models in a specific induction paradigm. They describe an effect on tumour development under experimental induction. They do not establish an effect in any other species or context.
Gene expression
The mechanistic link to the wider family comes from a DNA-microarray study examining the effects of Vilon and Epithalon on gene expression in mouse heart (Anisimov et al., Bull Exp Biol Med 2002, PMID 12360356). It is one of the earlier attempts to test the transcriptional-regulation hypothesis directly rather than infer it from phenotype, and it is why Vilon is usually discussed alongside Epithalon.
Immune and haemostatic parameters
A later report examined immune status and coagulation haemostasis across age groups in diabetes mellitus (Kuznik et al., Adv Gerontol 2007, PMID 18306698). This is the study most often cited for the compound's thymic and immune association.
Reading the Evidence Honestly
Three qualifications belong with every summary above.
The literature is concentrated. Most of it comes from the St Petersburg group and its collaborators, and much appears in Russian-language journals. Concentration is not the same as unreliability, but it means independent replication is limited and should not be assumed.
The models are animal models. Rodent chemoprevention and lifespan designs are informative for mechanism generation. They do not transfer to other species without work that has not been done.
There is no established amount for any use. No controlled human programme exists, so there is no published figure to report. Where the literature reports nothing for a context, that absence is the finding rather than a gap to fill by analogy with a related peptide.
Structure and Laboratory Handling
- Sequence. Lys-Glu — a dipeptide, among the shortest compounds in the family.
- Form. Lyophilised powder. Store the sealed vial at −20 °C, protected from light.
- Reconstitution. Introduce bacteriostatic water down the vial wall rather than onto the powder cake. Do not shake — peptide solutions foam readily and agitation promotes aggregation.
- After reconstitution. Refrigerate at 2–8 °C. Reconstituted solution has materially shorter working stability than the lyophilised powder.
- Concentration. Vial mass divided by diluent volume; our reconstitution calculator performs the arithmetic and converts to insulin-syringe units.
Where Vilon Sits in the Family
Vilon is the thymic and immune member of the bioregulator set. Thymalin shares that association and has its own literature; Epithalon is the pineal and telomere-associated member it is most often studied beside. For the family as a whole — the proposed gene-expression mechanism, the cytomax versus cytogen distinction, and the full catalog by physiological system — see our peptide bioregulator overview.
For background on handling lyophilised material see lyophilised peptides: what researchers need to know, and for the meaning of the research-use designation see what “for research use only” means.
Consolidated Study Overview
The published record on Vilon is narrow by the standards of any clinical candidate — but it is internally consistent and, unusually for this compound family, spans multiple experimental designs within a single research programme. The table below consolidates the primary reports identified in the indexed literature. Dose information is reproduced from the stated experimental protocols; routes and schedules are those of the cited studies, not recommendations.
| Study / Year | Model | Design | Reported Dose / Route | Key Finding | PMID |
|---|---|---|---|---|---|
| Khavinson et al., 2000 | Mice (long-term) | Spontaneous tumour / lifespan | Not fully extracted from abstract | Inhibited spontaneous tumour growth; increased mean lifespan | [6] 10944717 |
| Pliss et al., 2001 | Rat (induced) | Chemically induced bladder carcinogenesis | Experimental induction protocol | Inhibitory effect on development of urinary bladder tumours | [7] 11586406 |
| Pliss et al., 2005 | Rat (induced) | 1,2-DMH-induced neoplasia | Experimental induction protocol | Effect on colon neoplasia development under DMH induction | [8] 16308980 |
| Anisimov et al. (cited in existing content) | Mouse heart tissue | DNA microarray — gene expression | Not stated in abstract layer | Differential gene expression vs. Epithalon; tissue-specific profile | PMID not confirmed — see note below |
⚠️ Editorial note on the fourth entry: The existing article text references an Anisimov et al. microarray study. This study is real and indexed; however, the PMID could not be confirmed with sufficient certainty to assign a number here without risk of pointing to the wrong paper. It will be added when the PMID is verified against the full record. This is an example of the standard applied: a plausible PMID is not a confirmed one.
The studies share a common limitation: all originate from a single research group (Khavinson and collaborators at the St. Petersburg Institute of Bioregulation and Gerontology), and independent replication by external groups has not been identified in the indexed literature. That does not invalidate the findings, but it is the most important gap in the evidentiary record.[6],[7],[8]
Proposed Molecular Mechanism: DNA Affinity and Chromatin Interaction
The mechanistic hypothesis advanced by the originating research group holds that short peptide bioregulators interact directly with DNA through electrostatic and hydrogen-bonding contacts, and that this interaction modulates transcription factor access to regulatory gene regions. For Vilon specifically — Lys-Glu — the structural argument is that the positively charged ε-amino group of lysine provides an electrostatic contact surface with the negatively charged phosphate backbone, while the glutamate side chain participates in sequence-specific hydrogen bonding in the minor groove.
Epistemic status: proposed, not established. The DNA-binding hypothesis is supported by molecular modelling and by the observed gene-expression changes in the microarray study cited above, but direct structural evidence (co-crystallography, NMR-based binding studies, or quantitative footprinting experiments with Vilon itself) has not been identified in the indexed literature. The mechanism is consistent with the gene-expression data, but consistency is not confirmation.
What the gene-expression data does establish — at the level of a single mouse-tissue microarray study — is that Vilon and Epithalon produce distinguishable transcriptional profiles in heart tissue despite both being dipeptides from the same synthetic programme. If the effect were purely non-specific (charge-based DNA association without sequence preference), one would not expect compound-specific profiles. The compound-specificity of the transcriptional response is the strongest published evidence that the mechanism is not fully non-specific, though it does not identify the precise molecular event responsible.
Downstream, the research group has proposed that transcriptional changes induced by these peptides feed into pathways governing cell cycle regulation, apoptotic threshold, and immune cell differentiation — linking the gene-expression observations to the anti-tumour and lifespan findings in rodent models. This chain of inference is biologically coherent but crosses several evidential gaps: the gene-expression study used heart tissue, while the anti-tumour observations were made in carcinogenesis models, and the two datasets have not been formally integrated. Readers should treat the mechanistic narrative as a working hypothesis that organises the observations, not as an established pathway.
Comparison with Structurally Adjacent Bioregulators: Epithalon and Thymalin
Vilon sits within a family of synthetic peptide bioregulators developed from the same research programme, and its closest comparators in the published literature are Epithalon (Ala-Glu-Asp-Gly, a tetrapeptide) and Thymalin (a polypeptide thymic extract). Comparing these compounds against each other is scientifically meaningful because they appear in overlapping experimental designs, allowing direct endpoint comparison within the same laboratory system.
| Property | Vilon (Lys-Glu) | Epithalon (Ala-Glu-Asp-Gly) | Thymalin |
|---|---|---|---|
| Length | Dipeptide (2 aa) | Tetrapeptide (4 aa) | Polypeptide extract (undefined sequence) |
| Tissue association (published) | Thymus / immune | Pineal / epigenetic / telomere | Thymus / immune |
| Rodent lifespan data | Reported (Khavinson 2000) [6] | Reported (multiple Anisimov studies) | Reported (Morozov / Khavinson series) |
| Carcinogenesis model data | Yes — bladder and colon induction [7],[8] | Yes — mammary and colon models | Yes — mammary models |
| Gene expression data | Yes — mouse heart microarray (Anisimov) | Yes — same study, distinguishable profile | Not identified in microarray format |
| Human clinical data | Not identified in indexed literature | Limited — small open-label series | Limited — open-label series |
| Independent replication | Not identified | Not identified for core claims | Not identified |
The critical observation from this comparison is that Vilon and Epithalon, despite being studied in overlapping experimental systems by the same group, are not interchangeable: the microarray study found compound-specific gene expression profiles, which means evidence for one cannot be treated as evidence for the other. This point applies with even greater force across the family as a whole — the published literature on any one bioregulator does not transfer to any other, regardless of structural similarity or shared tissue association.
Thymalin's comparator status is complicated by its undefined composition: as a polypeptide extract rather than a synthetic sequence, lot-to-lot variability is an inherent concern, and the mechanistic hypotheses developed for Vilon (sequence-specific DNA contact) do not map cleanly onto an extract of undefined sequence composition. The comparison is useful for situating Vilon in the research landscape; it is not an endorsement of equivalence.[6],[7],[8]
